Effect of Zoledronic Acid Versus Bone Density of Lumbar
ID Number 05-0982-00215Principal Investigator(s)
Department(s) or Division(s)
Obstetrics, Gynecology, and Reproductive Science
This purpose of this study is to evaluate if Zoledronic acid may prevent bone loss in women after surgically induced menopause. Premenopausal women with no history of malignancies who recently underwent removal of both ovaries are qualified for the study. Half of the women will be allocated to receive three doses of intravenous Zoledronic acid. The study would like to evaluate the potential benefit of this drug in preventing bone loss from menopause.
Linus Chuang, MD
Recruiting Patients: No